Keynote Speakers
特邀专家

Prof. Xiaohua Douglas Zhang
University of Macau, China

Dr. Xiaohua Douglas Zhang is a professor in University of Macau, a fellow in the American Statistical Association, an elected member of International Statistical Institute and a senior member of IEEE. He earned his Ph.D. in statistics from Carnegie-Mellon University, PA, USA. Before joining UM in 2016, Dr. Zhang was a Senior Principal Scientist in Merck Research Laboratories, West Point, USA. He had worked there for >14 years, including the establishment/management (as a director) a biostatistics team supporting projects in drug discovery and clinical trials and the mentoring of junior staff and summer interns in both USA and China. He is conducting research on digital health/medicine, quantitative genomics and statistical omics. Dr. Zhang is the single author of a book "Optimal High-Throughput Screening" published by Cambridge University Press in 2011. The novel methods developed by Dr. Zhang and his colleagues along with their applications have a profound impact on the high throughput screening (HTS) research field, especially in RNAi HTS research. One of his co-authored articles had been highlighted in Nature Medicine’s year-end review on Notable Advances in 2008. Dr. Zhang is the founder and chair of the Executive Board of Macau Association for Bioinformatics and have organized many scientific conferences. He has been invited to serve as a critical reviewer for papers submitted to Nature, Nature Methods and so on, as an Expert Evaluator for grant proposals for multiple panels in USA, Europe, Hong Kong and mainland China.

Speech Title: Data Analysis and AI Application of High-Throughput Genomic Biotechnologies
Abstract:
By laying out in order the 3.2 billion units of our DNA after the completion of the Human Genome Project, researchers sparked a firestorm of discovery and an explosion of genomic knowledge. Accompanied with them are the rapidly emerging novel genomic technologies including microarrays, high-throughput sequencing, RNA interference high-throughput screening etc. All these launch the high-throughput genotyping era in which data analysis including artificial intelligent (AI) modeling should revolutionize the management of health and treatment of diseases. In this presentation, I will first describe our work in data analysis for high-throughput genotyping with focus on high-throughput RNAi screens and then we will show one of our studies with an application of using AI model on high-throughput sequencing data to predict the prognosis and therapy of breast cancer.





Prof. Jimmy Liu
Southern University of Science and Technology, China

Prof. Jimmy Liu graduated from the Department of Computer Science of the University of Science and Technology of China in 1988. He further obtained his master and doctoral degrees in Computer Science from the National University of Singapore. In 2004, he started the Intelligent Medical Imaging Research Team (iMED Singapore, A*STAR) and grew it to become one of the world's largest ophthalmic medical image processing team, focusing on ophthalmic Artificial Intelligence research. Jimmy was the chairman of the IEEE Singapore Biomedical Engineering Society in Singapore.
In March 2016, Jimmy returned to China and founded the iMED China (Ningbo) team. He was the senior professor and founding director of the Cixi Institute of Biomedical Engineering (CIBE) of the Chinese Academy of Sciences.
In February 2019, he joined the Department of Computer Science and Engineering of the Southern University of Science and Technology to establish iMED China(Shenzhen). .He is devoting his time to more fundamental eye-brain imaging, Artificial Intelligence, precision medicine, and surgical robotics research.

Speech Title: Intelligent Ocular Imaging Research and IMED Team latest research update 2021
Abstract:
In the talk, Jimmy will update the ocular imaging research work in the past years. He will share his AI-based eye image processing work on various ocular imaging modalities. He will cover the following 4 areas conducted in IMED Team (Singapore, Ningbo and Shenzhen): ocular disease screening, robot assisted eye micro-surgery, ocular biometrics, as well as ocular medical informatics using genome study. He will introduce the current issues, technologies and approaches in this inter-disciplinary research area, and introduce his latest research work in 2020/2021 in details.